STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study

STAT PlusBiotech Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study Drug could become new treatment option, and a blockbuster, if data hold up in late-stage trials Manage alerts for this article Email this article Share this article By Adam FeuersteinApril 27, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.

You can reach Adam on Signal at stataf.54. A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a mid-stage clinical trial, its maker, Oruka Therapeutics, reported Monday. Separately, Oruka said an updated analysis of blood exposure levels supported the potential for the drug, ORKA-001, to be injected just once per year.

Advertisement Oruka still needs to conduct late-stage clinical trials, but Monday’s results bolster ORKA-001’s potential to become a new treatment for the autoimmune skin disease with remission rates equal to or greater than current commercial blockbusters Skyrizi and Bimzelx, while requiring fewer injections. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%!

2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, chronic diseases, drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.

You can reach Adam on Signal at stataf.54. STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Recommended Biotech April 27, 2026 STAT Plus: Veradermics’ hair loss drug succeeds in late-stage trial Biotech April 24, 2026 STAT Plus: FDA to speed up review of three psychedelics as mental health treatments Advertisement The Readout April 24, 2026 STAT Plus: Sanofi MS drug gets positive review in Europe following FDA Biotech April 23, 2026 STAT Plus: Trump celebrates closing first round of drug pricing deals, promises more ahead The Readout April 23, 2026 STAT Plus: Sanofi research priorities in flux as new CEO logs in Subscriber Picks